Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis, has been extensively studied and over-expression is seen in many cancers. Today, VEGF is targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a standard treatment for many cancers, including colorectal and non-small cell lung cancer.

1. VEGF Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011
ReportsnReports.com adds Biopharm Reports Publishers Market Research Report “VEGF
Inhibition: Therapy-Indicating and Prognostic Biomarkers, 2011’’ to its store.
Vascular Endothelial Growth Factor (VEGF), which plays an important role in angiogenesis,
has been extensively studied and over-expression is seen in many cancers. Today, VEGF is
targeted using antibodies and tyrosine kinase inhibitors, and antiangiogenic therapy is a
standard treatment for many cancers, including colorectal and non-small cell lung cancer.
While VEGF inhibitors such as bevacizumab (Avastin®) provide valuable treatment options,
these benefits are not seen in all patients and cancer types. Today, there is an urgent need
for predictive biomarkers to enable those patients most likely to benefit from VEGF
inhibition, to be identified. This report provides a review of findings to date on biomarkers
associated with the use bevacizumab (Avastin®); both therapy-indicating and prognostic.
Browse: VEGF Biomarkers 2011
The identification of therapy-indicating and prognostic biomarkers relating to antiangiogenic
therapy is in its early stages, however important advances have been made. This report
identifies the latest findings on ten different cancers and includes an evaluation of candidate
biomarkers as a basis for interpreting patient outcomes according to RECIST criteria, and
evaluates existing bevacizumab-containing treatments and drug combinations.
Key content:
 A comprehensive review of clinical studies that have identified biomarkers that are either
therapy-indicating in respect of bevacizumab (Avastin®) or indicative of patient
prognosis
 Biomarkers identified or further evaluated in the last three years, up until October 2011.
From a background of extensive research on bevacizumab (Avastin®) and VEGF-related
biomarkers, the most important findings have been identified for their significance and
value to patients and in designing clinical trials
 Covering more than ten cancers including colorectal, ovarian, renal, breast, pancreatic,
prostate, lung and liver cancers
 Findings based on clinical trial findings including patient numbers, statistics and RECIST
criteria
 Studies indicate drug type associations together with comparative therapies
 Descriptions and explanation of all biomarkers identified roteins, genotypes, imaging
etc)
 Biomarker associations are categorised according to three broad criteria, namely
“positive-therapy-indicating” (response, improved response, improved outcome or
prognosis), “non-therapy-indicating” (no differences in tumour response, outcome or
prognosis) and “negative-therapy-indicating” (adverse events, poor outcome or
prognosis)

2. Table of Contents
Executive Summary
Chapter-1: Background
1.1. VEGF Inhibition
1.2. Bevacizumab
1.3. Biomarkers
1.4. This Report
Chapter-2: Colorectal Cancer: Candidate Biomarkers identified in Patients
receiving Bevacizumab-containing Therapies
Summary
2.1. Introduction
2.2. Glycoprotein
2.3. Protein
2.4. Protein
2.5. Cells
2.6. Genetic
2.7. Physical
2.8. Genetic
2.9. Protein
2.10. Proteins
2.11. Proteins and Genetic
2.12. Image
2.13. Proteins
2.14. Protein
Chapter-3: Breast Cancer: Candidate Biomarkers identified in Patients receiving
Bevacizumab-containing Therapies
Summary
3.1. Introduction
3.2. Protein
3.3. Protein
3.4. Protein
3.5. Protein
3.6. Protein
3.7. Genetic
3.8. Protein
Chapter-4: Renal Cancer: Candidate Biomarkers identified in Patients receiving
Bevacizumab-containing Therapies
Summary
4.1. Introduction
4.2. Image
4.3. Protein
4.4. Physical
4.5. Protein
4.6. Body Characteristic

3. Chapter-5: Ovarian Cancer: Candidate Biomarkers identified in Patients receiving
Bevacizumab-containing Therapies
Summary
5.1. Introduction
5.2. Proteins
5.3. Proteins
5.4. Proteins
5.5. Proteins
Chapter-6: Lung Cancer: Candidate Biomarkers identified in Patients receiving
Bevacizumab-containing Therapies
Summary
6.1. Introduction
6.2. Physical Parameter
6.3. Protein
6.4. Genetic
6.5. Protein
Chapter-7: Liver Cancer: Candidate Biomarkers identified in Patients receiving
Bevacizumab-containing Therapies
Summary
7.1. Introduction
7.2. Protein
7.3. Image
Chapter-8: Other Cancers: Candidate Biomarkers identified in Patients receiving
Bevacizumab-containing Therapies
Summary
8.1. Introduction
8.2. Proteins
8.3. Proteins
8.4. Protein
8.5. Protein
8.6. Physical
8.7. Physical
8.8. Physical
Chapter-9: Discussion
9.1. Overview
9.2. Colorectal Cancer
9.3. Breast Cancer:
9.4. Renal Cancer:
9.5. Ovarian Cancer
9.6. Lung Cancer
9.7. Liver Cancer
9.8. Other Cancers
9.9. Conclusions

4. List of Tables
Table 2.1: Candidates biomarkers identified in colorectal cancer patients receiving
bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 3.1: Candidates biomarkers identified in breast cancer patients receiving
bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 4.1: Candidates biomarkers identified in renal cancer patients receiving bevacizumab-
containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 5.1: Candidates biomarkers identified in ovarian cancer patients receiving
bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 6.1: Candidates biomarkers identified in lung cancer patients receiving bevacizumab-
containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 7.1: Candidates biomarkers identified in liver cancer patients receiving bevacizumab-
containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 8.1: Candidates biomarkers identified in other cancer patients receiving bevacizumab-
containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.1: Protein candidate biomarkers identified in cancer patients receiving bevacizumab-
containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.2: Genetic candidate biomarkers identified in cancer patients receiving
bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.3: Image-based candidate biomarkers identified in cancer patients receiving
bevacizumab-containing therapies (cancer, biomarker, biomarker type, drug therapies)
Table 9.4: Other candidate biomarkers identified in cancer patients receiving bevacizumab-
containing therapies (cancer, biomarker, biomarker type, drug therapies)
List of Figures
Figure 9.1: Candidate biomarkers types identified in cancer patients receiving bevacizumab-
containing therapies
Figure 9.2: Cancer types evaluated for biomarkers identified in cancer patients receiving
bevacizumab-containing therapies
Figure 9.3: Author countries (identified in this report) of cancers evaluated for biomarkers
identified in cancer patients receiving bevacizumab-containing therapies
Latest Market Research Reports:
 North American Fire and Life Safety Market
 Brazilian Industrial Protective Footwear Market
 Drug Repositioning: New Technologies, Business Models & Strategies for Successful
Development
 On-Trade Alcoholic Drinking Trends: Differentiating consumer on-trade drinking
occasions to capitalize on value generating opportunities
 Recycling Equipment Market in Singapore – Singapore recycling equipment market
About Us:
ReportsnReports is an online library of over 75,000 market research reports and in-depth
market research studies & analysis of over 5000 micro markets. We provide 24/7 online and
offline support to our customers. Get in touch with us for your needs of market research
reports.
Follow us on Twitter: http://twitter.com/marketsreports
Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689

5. Contact:
Mr. Priyank
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: + 1 888 391 5441
E-mail: sales@reportsandreports.com
http://www.reportsnreports.com
Visit Our Blog : Market Research Reports